<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-HTVBN9F1</identifier><date>2020</date><creator>Boc, Marko</creator><creator>Hribernik, Nežka</creator><creator>Ignjatović, Marija</creator><creator>Knez Arbeiter, Jasna</creator><creator>Mesti, Tanja</creator><creator>Ocvirk, Janja</creator><creator>Reberšek, Martina</creator><relation>documents/doc/H/URN_NBN_SI_doc-HTVBN9F1_001.pdf</relation><relation>documents/doc/H/URN_NBN_SI_doc-HTVBN9F1_001.txt</relation><format format_type="issue">1</format><format format_type="volume">54</format><format format_type="type">article</format><format format_type="extent">str. 119-127, XII</format><identifier identifier_type="DOI">10.2478/raon-2020-0003</identifier><identifier identifier_type="ISSN">1318-2099</identifier><identifier identifier_type="COBISSID">3451515</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-HTVBN9F1</identifier><language>eng</language><language>slv</language><publisher>Association of Radiology and Oncology</publisher><source>Radiology and oncology (Ljubljana)</source><rights>BY</rights><subject language_type_id="slv">imunoterapija</subject><subject language_type_id="slv">metastaski melanom</subject><subject language_type_id="slv">pembrolizumab</subject><subject language_type_id="slv">zdravljenje</subject><title>real-world experience</title><title>Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab</title></Record>